Literature DB >> 16715120

Neuropeptide Y2 receptors are involved in enhanced neurogenic vasoconstriction in spontaneously hypertensive rats.

Kathryn A Gradin1, Carsten L Buus, Jia-Yi Li, Ole Frøbert, Ulf Simonsen.   

Abstract

1. The present study addressed the role of neuropeptide (NPY) Y2 receptors in neurogenic contraction of mesenteric resistance arteries from female spontaneously hypertensive rats (SHR). Arteries were suspended in microvascular myographs, electrical field stimulation (EFS) was performed, and protein evaluated by Western blotting and immunohistochemistry. 2. In vasopressin-activated endothelium-intact arteries, NPY and fragments with selectivity for Y1 receptors, [Leu31,Pro34]NPY, Y2 receptors, NPY(13-36), and rat pancreatic polypeptide evoked more pronounced contractions in segments from SHR than in Wistar Kyoto (WKY) arteries, even in the presence of the Y1 receptor antagonist, BIBP3226 (0.3 microM, (R)-N(2)-(diphenacetyl)-N-[(4-hydroxyphenyl)methyl]D-arginineamide). 3. In the presence of prazosin and during vasopressin activation, EFS-evoked contractions were larger in arteries from SHR compared to WKY. EFS contractions were enhanced by the Y2 receptor selective antagonist BIIE0246TF (0.5 microM, (S)-N2-[[1-[2-[4-[(R,S)-5,11-dihydro-6(6h)-oxodibenz[b,e]azepin-11-y1]-1-piperazinyl]-2-oxoethyl]cyclo-pentyl-N-[2-[1,2-dihydro-3,5 (4H)-dioxo-1,2-diphenyl-3H-1,2,4-triazol-4-yl]ethyl]-argininamide), reduced by BIBP3226, and abolished by the combination of BIBP3226 and BIIE0246TF. 4. Immunoblotting showed NPY Y1 and Y2 receptor expression to be similar in arteries from WKY and SHR, although a specific Y2 receptor band at 80 kDa was detected only in arteries from WKY. 5. Immunoreaction for NPY was enhanced in arteries from SHR. In contrast to arteries from WKY, BIIE0246TF increased NPY immunoreactivity in EFS-stimulated arteries from SHR. 6. The present results suggest that postjunctional neuropeptide Y1 and Y2 receptors contribute to neurogenic contraction of mesenteric small arteries. Moreover, both enhanced NPY content and altered neuropeptide Y1 and Y2 receptor activation apparently contribute to the enhanced neurogenic contraction of arteries from SHR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16715120      PMCID: PMC1751866          DOI: 10.1038/sj.bjp.0706774

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

Review 1.  BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: a review of its pharmacological properties.

Authors:  H N Doods; H A Wieland; W Engel; W Eberlein; K D Willim; M Entzeroth; W Wienen; K Rudolf
Journal:  Regul Pept       Date:  1996-08-27

Review 2.  XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors.

Authors:  M C Michel; A Beck-Sickinger; H Cox; H N Doods; H Herzog; D Larhammar; R Quirion; T Schwartz; T Westfall
Journal:  Pharmacol Rev       Date:  1998-03       Impact factor: 25.468

Review 3.  Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control.

Authors:  R E Malmström
Journal:  Acta Physiol Scand Suppl       Date:  1997

4.  Age-related decrease of calcitonin gene-related peptide-containing vasodilator innervation in the mesenteric resistance vessel of the spontaneously hypertensive rat.

Authors:  H Kawasaki; A Saito; K Takasaki
Journal:  Circ Res       Date:  1990-09       Impact factor: 17.367

5.  Increased vasopressor actions of intraventricular neuropeptide Y-(13-36) in spontaneously hypertensive versus normotensive Wistar-Kyoto rats. Possible relationship to increases in Y2 receptor binding in the nucleus tractus solitarius.

Authors:  J A Aguirre; P B Hedlund; J A Narváez; B Bunnemann; D Ganten; K Fuxe
Journal:  Brain Res       Date:  1995-07-03       Impact factor: 3.252

6.  Interactions between neuropeptide Y and the adenylate cyclase pathway in rat mesenteric small arteries: role of membrane potential.

Authors:  D Prieto; C Buus; M J Mulvany; H Nilsson
Journal:  J Physiol       Date:  1997-07-15       Impact factor: 5.182

7.  Possible location and function of neuropeptide Y receptor subtypes in the rat mesenteric arterial bed.

Authors:  M A McAuley; T C Westfall
Journal:  J Pharmacol Exp Ther       Date:  1992-06       Impact factor: 4.030

8.  Regional involvement of an endothelium-derived contractile factor in the vasoactive actions of neuropeptide Y in bovine isolated retinal arteries.

Authors:  D Prieto; U Simonsen; N C Nyborg
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

9.  Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.

Authors:  R Abounader; J G Villemure; E Hamel
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

10.  Characterization of neuropeptide Y receptors mediating contraction, potentiation and inhibition of relaxation.

Authors:  T Nilsson; J You; X Sun; T Hedner; L Edvinsson
Journal:  Blood Press       Date:  1996-05       Impact factor: 2.835

View more
  8 in total

Review 1.  Neuropeptide Y Y2 receptor in health and disease.

Authors:  S L Parker; A Balasubramaniam
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

2.  Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries.

Authors:  Maj Bangshaab; Alejandro Gutierrez; Khiem Dinh Huynh; Jakob Schöllhammer Knudsen; Daniel Dias Rufino Arcanjo; Asbjørn G Petersen; Jørgen Rungby; Michael Gejl; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2018-12-09       Impact factor: 8.739

3.  Functional pharmacological characterization of SER100 in cardiovascular health and disease.

Authors:  Inmaculada C Villar; Kristen J Bubb; Amie J Moyes; Eva Steiness; Trygve Gulbrandsen; Finn Olav Levy; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

Review 4.  Neuropeptide Y and neurovascular control in skeletal muscle and skin.

Authors:  Gary J Hodges; Dwayne N Jackson; Louis Mattar; John M Johnson; J Kevin Shoemaker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-07-01       Impact factor: 3.619

5.  Alterations in sympathetic neuroeffector transmission to mesenteric arteries but not veins in DOCA-salt hypertension.

Authors:  Jinwoo Park; James J Galligan; Gregory D Fink; Greg M Swain
Journal:  Auton Neurosci       Date:  2009-11-13       Impact factor: 3.145

Review 6.  Obesity and appetite control.

Authors:  Keisuke Suzuki; Channa N Jayasena; Stephen R Bloom
Journal:  Exp Diabetes Res       Date:  2012-08-01

Review 7.  Genetic Programming of Hypertension.

Authors:  Sun-Young Ahn; Charu Gupta
Journal:  Front Pediatr       Date:  2018-01-22       Impact factor: 3.418

8.  Neuropeptide Y-mediated sex- and afferent-specific neurotransmissions contribute to sexual dimorphism of baroreflex afferent function.

Authors:  Yang Liu; Di Wu; Mei-Yu Qu; Jian-Li He; Mei Yuan; Miao Zhao; Jian-Xin Wang; Jian He; Lu-Qi Wang; Xin-Jing Guo; Meng Zuo; Shu-Yang Zhao; Mei-Na Ma; Jun-Nan Li; Weinian Shou; Guo-Fen Qiao; Bai-Yan Li
Journal:  Oncotarget       Date:  2016-10-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.